MediWound walked into this print as a high-growth, high-expectation biotech, yet the stock barely moved, up just 0.04% on the day and still down over the past week, month and quarter. That flat reaction hides a more complicated headline. Q2 revenue came in at US$3.1m, while the company booked a net loss of US$7.4m, or US$0.57 per share, as spending on EscharEx Phase III work and NexoBrid scale-up pulled harder on the income statement.

Is MediWound trading at a justifiable premium P/S of 14.8x, or are investors overpaying for a stock that is still loss making with recent dilution in the rear view? See how that valuation stacks up against the US Pharmaceuticals industry and close peers in the full valuation analysis for MediWound

Q2 2026 Earnings Summary

• Revenue Q2 2026 vs Q2 2025: US$3.1m vs US$5.7m (revenue declined, partly tied to timing of government funded development revenue)
• Net Loss Q2 2026 vs Q2 2025: US$7.4m loss vs US$13.3m loss (loss narrowed)
• Basic EPS Q2 2026 vs Q2 2025: US$0.57 loss per share vs US$1.23 loss per share (loss per share narrowed)
• Gross Margin Q2 2026 vs Q2 2025: 10.9% vs prior period, supported by higher gross profit (margin pressured by one time facility scale up impact)

Prefer clean charts over long paragraphs and raw spreadsheets when trying to understand MediWound? View a clear visual summary of how the stock is valued with our full company report for MediWound.

MediWound bull case hinges on execution milestones

Bulls argue MediWound is steadily de risking EscharEx and NexoBrid while government contracts backfill the income statement. The latest quarter offers mixed evidence. Management reaffirmed 2026 revenue guidance of US$24m to US$26m and confirmed that EscharEx VALU Phase III enrollment and the interim sample size check are still targeted by the end of Q1 2027. That supports the view that clinical timelines are intact. Government backed work also advanced. The Vericel master services agreement has moved into its first development program and BARDA funded and Department of War funded projects are in motion, which management expects to convert into H2 2026 revenue. However, H1 2026 revenue of US$4.6m versus US$9.7m a year earlier shows the BARDA timing swing cuts both ways. Execution is progressing, but the portfolio is not yet carrying the cost base.

MediWound bear case flags cash burn and concentration

The bear story centers on heavy cash burn, reliance on two key assets and execution risk in manufacturing and government revenue. Q2 2026 data reinforces several of those concerns. Revenue of US$3.1m and H1 cash of about US$36m against roughly US$20m of H1 burn highlight a business still far from self funding. Adjusted EBITDA loss widened to US$8.3m and operating loss reached US$9.5m in the quarter. EMA requested modifications to the expanded NexoBrid facility, with commercial supply from that site pushed to H2 2027 at the earliest. This delays manufacturing relief. Revenue is also concentrated. H1 sales roughly halved year on year as BARDA development revenue shifted, showing how timing or approval issues can swing results. Recent share performance, down 5.8% over 7 days and 17.4% over 90 days, suggests this risk profile is front of mind for investors.

Compare MediWound's internal execution story against external expectations and see whether analysts think this premium P/S and cash burn profile are justified. See the consensus price target analysis for MediWound to find out how Wall Street is calibrating its targets after this earnings print.

Stay Ahead With Simply Wall St

If the mix of premium P/S, cash burn and EscharEx milestones has put MediWound on your radar, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch how the thesis develops. After you decide to take a position, keep your focus with a Portfolio Command Center that cuts through noise and surfaces only the key changes that matter to your holdings. For a broader view on MediWound and other stocks, tap into crowd insights and debate through the Community to see how different investors are weighing the same data. By identifying potential catalysts and risks early, you can act more quickly on well-researched decisions and work to stay ahead of the market.

Seeking Alternatives Beyond MediWound Today

Fresh ideas often move first. By the time momentum is strong, the most attractive entry points may no longer be available. Scan curated stock sets that are still under the radar and consider getting in earlier in the move.

• Identify resilient cash generators that could be building quiet breakout momentum by reviewing the curated list of solid balance sheet and fundamentals stocks (50 results) before the broader market begins paying closer attention.
• Explore potential income streams while yields are still elevated by scanning the hand picked 10 dividend fortresses before prices adjust and payouts are affected by re-ratings.
• Monitor early leaders in AI infrastructure where spending trends may be shifting by reviewing the focused 55 AI infrastructure stocks while conditions remain relevant and consider your next steps accordingly.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.